Study on clinical treatment of 30 cases of acute deep venous thrombosis
Discussion of Clinical Cases · 29.01.2026 · 11 (3) · 1-6
DOI: 10.5430/dcc.v11n3p1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Discussion of Clinical Cases, online erschienen am 29.01.2026. Verfasst von Junjie Wang und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Objective
To analyze the efficacy of the AngioJet thrombus aspiration system combined with catheter-directed thrombolysis (CDT) in treating acute deep venous thrombosis (ADVT).
Methods
Thirty patients with ADVT admitted to a tertiary A-grade hospital from January 2020 to March 2021 were randomly assigned to either the CDT group or the AngioJet group, with 15 patients in each group. The CDT group underwent catheterdirected thrombolysis, while the AngioJet group received the treatment with the AngioJet thrombus aspiration system. There were no statistically significant differences between the two groups in terms of gender, age, onset time, or thrombus type (p > .05). Thrombus clearance rates, limb edema resolution rates, total urokinase dosage, thrombolysis duration, and complications were compared between the two groups of patients with ADVT in this study.
Results
The AngioJet group demonstrated superior thrombectomy grading in comparison to the CDT group (Z = 2.340, p = .019). The limb edema resolution rate was significantly higher in the AngioJet group (93.33%) than that in the CDT group (53.33%) (p < .05). The thrombolysis duration in the AngioJet group (0.50 ± 0.11 h) was significantly shorter than that in the CDT group (72.14 ± 0.42 h) (p < .05). The urokinase dosage in the AngioJet group (18.51 ± 2.02 × 104 U) was significantly lower than that in the CDT group (85.34 ± 2.75 × 104 U) (p < .05). The incidence of complications in the AngioJet group (13.33%) was lower than that in the CDT group (26.67%), with no statistically significant difference (p > .05).
Conclusions
The AngioJet thrombus aspiration system demonstrates superior thrombus clearance efficacy in comparison to CDT in ADVT patients, with shorter thrombolysis duration, reduced urokinase dosage, and favorable clinical safety.
Zitieren
APA
Wang, J., & Han, B. (2026). Study on clinical treatment of 30 cases of acute deep venous thrombosis. Discussion of Clinical Cases, 11(3), 1-6. https://doi.org/10.5430/dcc.v11n3p1
Vancouver
Wang J, Han B. Study on clinical treatment of 30 cases of acute deep venous thrombosis. Discussion of Clinical Cases. 2026;11(3):1-6. doi:10.5430/dcc.v11n3p1
BibTeX
@article{Wang2026,
author = {Wang, Junjie and Han, Bo},
title = {Study on clinical treatment of 30 cases of acute deep venous thrombosis},
journal = {Discussion of Clinical Cases},
year = {2026},
volume = {11},
number = {3},
pages = {1--6},
doi = {10.5430/dcc.v11n3p1}
}
EUVIMED